$ESPR has received 9 mentions over the past 12 months from 2 distinct FinTwit voices, with the first mention appearing on 2025-07-26. @microcapclub, the dominant voice in discussions of Esperion Therapeutics, accounts for 8 of these mentions and specializes in long research on microcap stocks. The stock gained significant attention within this community, with one member reporting a +250% return over a 10-month period as of 2026-02-26.

On 2026-05-04, @ssi_invest posted the most recent mention, detailing a PE acquisition of $ESPR at $3.16 per share in cash plus a $0.39 per share contingent value right tied to net sales of bempedoic acid and bumetanide. The transaction represents a 58% upfront premium to the unaffected price, with expected closing in Q3 2026. The CVR structure provides equity-like optionality in a biotech buyout context while eliminating regulatory risk through a private equity take-private structure.